Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

All recorded activity

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
5
Confirmed lead rounds
0
4 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$1B
5 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series A1
Series B1

By primary sector

Biotech4
Hardware1

By country

United States5

Rounds

5 in all activity
Fab2

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

$500MSeries A
Participant
Ratio Therapeutics

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C
Role not disclosed
SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B
Role not disclosed
Cellares

Develops automated cell therapy manufacturing platforms

$257MSeries D
Role not disclosed